Bult Wouter, Vente Maarten A D, Vandermeulen Eva, Gielen Ingrid, Seevinck Peter R, Saunders Jimmy, van Het Schip Alfred D, Bakker Chris J G, Krijger Gerard C, Peremans Kathelijne, Nijsen Johannes F W
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Brachytherapy. 2013 Mar-Apr;12(2):171-7. doi: 10.1016/j.brachy.2012.08.001. Epub 2012 Sep 19.
Holmium-166 acetylacetonate microspheres ((166)Ho-AcAc-MS) are proposed as an intratumoral radioablation device. This article presents a pilot study in housecats with unresectable liver cancer. Feasibility and tolerability of intratumoral administrations of (166)Ho-AcAc-MS was investigated.
Three cats with unresectable liver tumors of different histotype were included. One cat had hepatocellular carcinoma (HCC), one had cholangiocarcinoma (CC), and one had a malignant epithelial liver tumor (MELT) of unspecified histotype. (166)Ho-AcAc-MS were injected percutaneously under ultrasound guidance into the tumors. Followup consisted of physical examinations and hematologic and biochemical analyses.
(166)Ho-AcAc-MS were administered to three liver tumor-bearing cats. The treatment was well tolerated and the clinical condition, that is body weight, alertness, mobility, and coat condition of the animals improved markedly. Most biochemical and hematologic parameters normalized shortly after treatment. Life of all cats was extended and associated with a good quality of life. The HCC cat that received 33-Gy tumor-absorbed dose was euthanized 6 months after the first administration owing to disease progression. The MELT cat received 99-Gy tumor dose and was euthanized 3 months posttreatment owing to bacterial meningitis. The CC cat received 333Gy and succumbed 4 months after the first treatment owing to the formation of a pulmonary embolism.
Percutaneous intratumoral injection of radioactive (166)Ho-AcAc-MS is feasible in liver tumor-bearing cats. The findings of this pilot study indicate that (166)Ho-AcAc-MS may constitute safe brachytherapeutic microspheres and warrant studies to confirm the clinical utility of this novel brachytherapy device.
提出将钬 - 166乙酰丙酮微球（（166）Ho - AcAc - MS）作为一种瘤内放射性消融装置。本文介绍了一项针对患有不可切除肝癌的家猫的初步研究。研究了瘤内注射（166）Ho - AcAc - MS的可行性和耐受性。
纳入三只患有不同组织学类型不可切除肝肿瘤的猫。一只猫患有肝细胞癌（HCC），一只患有胆管癌（CC），另一只患有组织学类型未明确的恶性上皮性肝肿瘤（MELT）。在超声引导下经皮将（166）Ho - AcAc - MS注入肿瘤。随访包括体格检查以及血液学和生化分析。
对三只患有肝肿瘤的猫给予了（166）Ho - AcAc - MS。该治疗耐受性良好，动物的临床状况，即体重、警觉性、活动能力和被毛状况明显改善。大多数生化和血液学参数在治疗后不久恢复正常。所有猫的寿命均延长，且生活质量良好。接受33 Gy肿瘤吸收剂量的HCC猫在首次给药后6个月因疾病进展而实施安乐死。MELT猫接受了99 Gy肿瘤剂量，在治疗后3个月因细菌性脑膜炎而实施安乐死。CC猫接受了333 Gy，在首次治疗后4个月因肺栓塞而死亡。
经皮瘤内注射放射性（166）Ho - AcAc - MS在患有肝肿瘤的猫中是可行的。这项初步研究的结果表明，（166）Ho - AcAc - MS可能构成安全的近距离治疗微球，有必要进行研究以证实这种新型近距离治疗装置的临床实用性。
